When will the FDA reclassify BPC-157 to Category 1?

As of Sun, 22 Nov 2026 00:49:22 UTC, Kalshi traders price Yes (5.0%). The market has $149K in volume and closes on Fri, 01 Jan 2027.

Updated:

Current odds

OutcomeChanceYes priceNo price
Yes5.0%5.0¢95.0¢

Market details

Resolution rules

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes. The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.

Sources

Related markets

More markets like this

A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use

DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.